People aged 60 years or older with a history of urinary tract infection (UTI) are at an increased risk of developing a bloodstream infection caused by an E. coli bacteria. Currently there is no approved vaccine to prevent blood infections caused by E.coli bacteria, so the purpose of this clinical trial is to evaluate the safety and effectiveness of an investigational vaccine in the prevention of bloodstream infections they can cause.

This is a randomised, double-blind placebo-controlled clinical trial, which means that participants will be randomly (by chance) assigned 50/50 to one of two vaccination groups in this study – 50% of participants will receive the active vaccine and 50 % will receive the placebo (contains no active medicine). Neither the study team, nor the participants themselves, will know which vaccination group people have been assigned to. The investigational vaccine or placebo will be given via a single intramuscular injection on Day 1 of the study.

Recruitment for this study ends in December 2023.


Anyone interested in knowing more about this trial can contact the Study Coordinator Bernadette Rickards on (07) 3346 5060 or by email